Adalimumab PK Bioequivalence Study to EU and US Sourced Humira

Healthy Volunteers Clinical Trial

Official title:

Single Center, Randomized, Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira, Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02472912
• Other study ID #: MYL-HEB-1001
• Secondary ID: 2014-000212-33
• Status: Completed
• Phase: Phase 1
• Start date: December 2014
• Est. completion date: June 2015

Study information

• Verified date: March 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira® Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults.

Description:

This is a single-center, randomized, double-blind, 3-way parallel study in 270 healthy adult male and female subjects. During this study, the PK bioequivalence of BMO-2, containing 40 mg adalimumab, will be compared to EU licensed Humira® (EU-Humira® ) (40 mg) and US licensed Humira® (US-Humira® ) (40 mg).

Randomization will be stratified by body weight (weight categories of 60.0-79.9 kg and 80.0-95.0 kg). After randomization, subjects will receive one of the following treatments: a single sc injection of 40 mg BMO-2, an equivalent sc injection of EU-Humira® (40 mg), or an equivalent sc injection of US-Humira® (40 mg).

Volunteers participation in the study is expected to finish with the follow-up visit, scheduled 70 days after the injection of study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 270
• Est. completion date: June 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Weight: 60.0-95.0 kg.

• Body mass index (BMI) : 19.0-30.0 kg/m2, inclusive

• Medical history without major pathology.

• Systolic blood pressure =150 mmHg and diastolic blood pressure =90 mmHg.

• Computerized (12-lead) electrocardiogram (ECG) recording without signs of clinically relevant pathology

• Nonsmoker or light smoker

• Ability and willingness to abstain from alcohol from 48 h prior to drug administration and 48h prior to ambulatory visits, and during the stays in the clinical research center until discharge from the in-house period.

• Fertile males and females participating in heterosexual sexual relations:willingness to use adequate contraception from screening until 90 days after the follow-up visit

• Females must not lactate and must have a negative pregnancy test at screening and at admission

• Differentiation of leukocytes, platelet count, hematocrit and hemoglobin results within the reference ranges. Minor deviations considered to lack any clinical relevance by the Principal Investigator can be accepted.

• All other values for hematology and for biochemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Principal Investigator.

Other protocol-defined inclusion/exclusion criteria may apply

Exclusion Criteria:

• History of relevant drug and/or food allergies.

• Hypersensitivity to Humira® or its constituents.

• Known history of previous exposure to anti TNF-alpha molecules.

• Any past or concurrent medical conditions potentially increasing the subject's risks. Examples of these include medical history with evidence of clinically relevant pathology (e.g., malignancies, demyelinating disorders).

• Presence of chronic obstructive pulmonary disease (COPD). Asthma in the childhood is allowed

• Any current active infections, including localized infections, or any recent history

• Treatment with non-topical medications (including over the counter medication, and herbal remedies such as St. John's Wort extract) within 7 days prior to study drug administration, with the exception of hormonal contraceptives, multivitamins, vitamin C, food supplements and a limited amount of acetaminophen, which may be used throughout the study.

• History of active tuberculosis or presence of active or latent tuberculosis.

• Having resided or traveled in regions where tuberculosis and mycosis are endemic within 90 days before screening, or who intend to visit such a region during the period of 3 months after dosing.

• Having received live vaccines during the past 4 weeks before screening or have the intention to receive vaccination during the study.

• Participation in a drug study within 60 days or 5 half-lives of the previous drug (if known), whichever is longer, prior to drug administration

• Donation of more than 500 mL of blood within 8 weeks prior to drug administration.

• History of alcohol abuse or drug addiction (including soft drugs like cannabis products).

• Positive urine drug screen (opiates, methadone, cocaine, amphetamines (including XTC or metamphetamines), cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants) and positive alcohol breath test.

• Positive screen on Hepatitis B surface antigen (HBsAg), anti-Hepatitis C virus antibodies (HCV), or anti-human immunodeficiency virus 1/2 antibodies (HIV).

Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Biological:
• BMO-2
Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
• EU-Humira
Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
• US-Humira
Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).

Locations

Country	Name	City	State
Belgium	SGS Belgium NV	Antwerp

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Inc.	Mylan GmbH

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve (AUC) of adalimumab.		1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71 days post subcutaneous injection.
Secondary	Frequency of Adverse Events		Up to 71 days.
Secondary	Safey variable - Tolerability (injection site reactions)	Tolerability assessments as measured by injection site reactions	Predose and 1, 2, 3, 7, 9, 36, and 71 days post subcutaneous injection.
Secondary	Safety variable - immunogenicity (Presence of anti-adalimumab antibodies)	Presence of anti-adalimumab antibodies	Day 1 (pre-dose) and Day 9, 29, and 71 days post subcutaneous injection.